Detail akcie electroCore Rg online

Business Summary: electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company focused on improving health through its non-invasive vagus nerve stimulation (nVNS) technology platform and related product offerings. The Company’s portfolio also includes Quell, a wearable, app and cloud-enabled neuromodulation platform that is indicated for the treatment of fibromyalgia symptoms and lower-extremity chronic pain. Its product categories include handheld, personal use medical devices for the management and treatment of certain medical conditions such as primary headaches, and handheld, personal use consumer products. Its products include gammaCore, Quell Fibromyalgia, Truvaga and TAC-STIM. Its gammaCore Sapphire is a prescription medical device that is used for a variety of primary headache conditions. Truvaga is a personal-use consumer electronics general wellness product that does not require a prescription and is available direct-to-consumer from electroCore at www.truvaga.com.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, electroCore, Inc. revenues increased 26% to $22.8M. Net loss increased 26% to $10.9M. Revenues reflect Truvaga segment increase of 30% to $2.1M, United States segment increase of 27% to $21.3M, Other segment increase of 60% to $131K. Higher net loss reflects Selling, general and administrative increase of 23% to $26.6M (expense), Interest expense increase from $128K to $772K (expense).